Origin Therapeutics is an actively-managed investment issuer providing investors with a diverse exposure to the psychedelic industry.
Stock Performance
Origin Therapeutics Holdings Inc. News 10 articles
- Origin Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
- Safe Supply and Origin Therapeutics Receive Conditional Approval for Listing On the CSE
- Origin Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
- Safe Supply and Origin Therapeutics Receive Conditional Approval for Listing on the CSE
- Origin Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
- Safe Supply and Origin Therapeutics Announces Engagement of Research Capital and Upsizing of Brokered Financing To $4 Million
- Origin Therapeutics’ Portfolio Company, Clairvoyant, Approved for Phase 2 Psilocybin Therapy Trial; First Clinical Site Initiated in Finland
- Origin Therapeutics’ Portfolio Company, Xpira Pharmaceuticals, Receives FDA Approval For Psilocybin Trial IND Application
- Innovation1 Biotech Appoints Frederick E. Pierce, II to its Board of Directors
- Innovation1 Biotech Announces Filing of Patent Application for Novel Combination Therapy Targeting Addiction